article Open AccessTop 1% cited
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
JNCI Journal of the National Cancer Institute · 2003 · Vol. 95(17) · pp. 1320–1329
Andreas du Bois✉(Helios Dr. Horst Schmidt Kliniken Wiesbaden)
Abstract
The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesEndometrial and Cervical Cancer TreatmentsMedicineCarboplatinHazard ratioTolerabilityInternal medicineProgression-free survivalOvarian cancerRandomized controlled trialClinical endpointPaclitaxel
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, PhytogenicCisplatinFemaleGermanyHumansMiddle AgedOvarian NeoplasmsPatient ComplianceQuality of LifeProportional Hazards ModelsOdds RatioSurvival Analysis
Citations
1,126
FWCI
55.67
field-weighted impact
References
28
Percentile
100%
vs. same field & year
Citations per year
Cited by
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Cancer · 2009 · 1,581 citations
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
European Journal of Cancer · 2010 · 1,070 citations
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
PLoS Medicine · 2008 · 815 citations
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Gynecologic Oncology · 2013 · 421 citations
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
European Journal of Cancer · 2006 · 535 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · 1,130 citations
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Gynecologic Oncology · 2016 · 363 citations
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
Annals of Oncology · 2012 · 1,008 citations
References
Statistical Methods for Rates and Proportions, 2nd ed
American Journal of Psychiatry · 1981 · 3,786 citations
WHO Handbook for Reporting Results of Cancer Treatment
British Journal of Cancer · 1982 · 2,201 citations
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy
International Journal of Radiation Oncology*Biology*Physics · 2000 · 808 citations
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Journal of Clinical Oncology · 1989 · 1,881 citations
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
JNCI Journal of the National Cancer Institute · 1993 · 15,705 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.